China's proposed regulatory scheme sets 45-day turnaround time for product decisions.
This article was originally published in The Gray Sheet
Executive SummaryCHINA'S PROPOSED MEDICAL DEVICE REGULATORY FRAMEWORK would provide for approval decisions within 45 days of processing registration applications from Chinese or offshore manufacturers, according to a "Guide to Product Registration and Advertisement Examination of Medical Devices" issued by the State Pharmaceutical Administration of China (SPAC). The regulatory plan must be approved by China's State Council before implementation can occur.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.